Finance

Beta
Lists
RARE:NASDAQ
Ultragenyx Pharmaceutical Inc
$30.77
+5.20%
(+1.52) 1D
$30.00
-2.50% (-0.77)
After hours
Closed: Jun 26, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RARE...
Open
$29.39
High
$30.99
Low
$29.36
Mkt. cap
3.03B
Avg. vol.
1.77M
Volume
17.18M
52-wk high
$42.37
52-wk low
$18.29
EPS
-$6.10
Beta
0.37
Shares outstanding
98.49M
No. of employees
1K
Open
$29.39
High
$30.99
Low
$29.36
Mkt. cap
3.03B
Avg. vol.
1.77M
Volume
17.18M
52-wk high
$42.37
52-wk low
$18.29
EPS
-$6.10
Beta
0.37
Shares outstanding
98.49M
No. of employees
1K
News stories
From sources across the web
Stock Traders Daily
Stock Traders Daily
·
13 hours ago
Liquidity Mapping Around (RARE) Price Events
Profile
Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases. Ultragenyx is based in Novato, CA and Brisbane, CA and has a presence in the Boston area, including a gene therapy plant under construction as of 2021. The company’s Latin American headquarters is located in Miami. Ultragenyx collaborates on product development with other companies including GeneTX, Kyowa Hakko Kirin, Mereo Biopharma and Daiichi Sankyo. Ultragenyx has three products Burosumab, Triheptanoin and Vestronidase alfa that have received FDA approval and several others currently in clinical trials. The company also holds the non-US commercial rights to Regeneron’s evinacumab-dgnb, which is approved by the FDA and EMA. Wikipedia
About Ultragenyx Pharmaceutical Inc
CEOEmil Kakkis
Employees1.37K
Founded2010
HeadquartersNovato, California, United States
SectorBiotechnology
Websiteultragenyx.com
Analyst ratings
Based on 15 analysts giving stock ratings to RARE in the past 3 months
Strong buy
Buy
14
Hold
1
Sell
0
12-month forecast
Based on 15 Wall Street analysts offering 12 month price targets for RARE in the last 3 months.
Highest
Current $30.77
$96.00 (+211.99%)
Average
$53.79 (+74.81%)
Lowest
$26.00 (-15.50%)
Analyst
Recommendation
Action
Price target
Projected
Date
Whitney Ijem
Canaccord Genuity
Buy
Maintained
$79.00
+156.7%
06/10/2026
Anupam Rama
J.P. Morgan
Buy
Maintained
$72.00
+134%
05/22/2026
Kristen Kluska
Cantor Fitzgerald
Buy
Reiterated
$96.00
+212%
05/20/2026
Gavin Clark-Gartner
Evercore ISI
Buy
Maintained
$33.00
+7.2%
05/11/2026
Ram Selvaraju
H.C. Wainwright
Buy
Reiterated
$50.00
+62.5%
05/11/2026
Debjit Chattopadhyay
Guggenheim
Buy
Maintained
$43.00
+39.7%
05/08/2026
Laura Chico
Wedbush
Hold
Maintained
$26.00
-15.5%
05/08/2026
Allison Bratzel
Piper Sandler
Buy
Maintained
$68.00
+121%
05/07/2026
Luca Issi
RBC Capital
Buy
Reiterated
$35.00
+13.7%
05/05/2026
Benjamin Burnett
Wells Fargo
Buy
Maintained
$47.00
+52.7%
05/06/2026
Maxwell Skor
Morgan Stanley
Buy
Maintained
$67.00
+117.7%
05/06/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$45.00
+46.2%
05/05/2026
Eliana Merle
Barclays
Buy
Maintained
$43.00
+39.7%
05/06/2026
Yaron Werber
TD Cowen
Buy
Maintained
$49.00
+59.2%
05/05/2026
Tazeen Ahmad
Bank of America Securities
Buy
Maintained
-
-
04/16/2026
Salveen Richter
Goldman Sachs
Hold
Downgraded
$25.00
-18.8%
03/24/2026
Jack Allen
Robert W. Baird
Buy
Maintained
$40.00
+30%
02/13/2026
Sami Corwin
William Blair
Buy
Maintained
-
-
02/13/2026
Joon Lee
Truist Financial
Buy
Maintained
$76.00
+147%
02/13/2026
Last report
May 5, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
-$1.54 / -$1.39
-10.94%miss
Revenue / Est. (USD)
136.00M / 157.93M
-13.89%miss
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
166.50M
159.93M
207.28M
136.00M
Cost of goods sold
187.74M
244.20M
232.62M
173.00M
Cost of revenue
187.74M
244.20M
232.62M
173.00M
Research and development expenses
-
-
-
16.00M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
86.65M
86.62M
87.94M
86.00M
Operating expense
86.65M
86.62M
87.94M
102.00M
Total operating expenses
274.38M
330.82M
320.56M
275.00M
Operating income
-107.89M
-170.89M
-113.28M
-139.00M
Other non operating income
2.14M
-1.04M
-934.00K
-
EBT including unusual items
-114.00M
-179.54M
-127.69M
-184.00M
EBT excluding unusual items
-114.00M
-180.22M
-127.17M
-154.00M
Income tax expense
947.00K
873.00K
870.00K
1.00M
Effective tax rate
-0.83%
-0.49%
-0.68%
-0.54%
Other operating expenses
-
-
-
-
Net income
-114.95M
-180.41M
-128.56M
-185.00M
Net profit margin
-69.04%
-112.81%
-62.02%
-136.03%
Earnings per share
-1.17
-1.81
-1.29
-1.54
Interest and investment income
5.79M
5.86M
6.51M
6.00M
Interest expense
-14.04M
-14.15M
-19.47M
-21.00M
Net interest expenses
-8.25M
-8.28M
-12.96M
-15.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
-99.27M
-162.28M
-104.50M
-131.00M
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
Give me an overview of RARE
Explore what’s possible
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer